WARSAW, Ind., Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.
The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.
Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (800) 330-6710 and using conference ID 7090861. International callers should dial +1 (213) 279-1505 and use conference ID 7090861.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.X.com/zimmerbiomet.
Contacts: Media Troy Kirkpatrick 614-284-1926 This email address is being protected from spambots. You need JavaScript enabled to view it. Kirsten Fallon 781-779-5561 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors David DeMartino 646-531-6115 This email address is being protected from spambots. You need JavaScript enabled to view it. Zach Weiner 908-591-6955 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$97.07 |
| Daily Change: | 3.55 3.80 |
| Daily Volume: | 1,780,613 |
| Market Cap: | US$19.240B |
November 14, 2025 November 07, 2025 November 05, 2025 October 28, 2025 October 21, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
